Compositions and Methods for Treating Burns
The present invention provides compositions and methods for treating burns comprising administering to a burn area of a subject in need thereof of a therapeutically effective amount of a composition comprising an anti-cytokine or anti-inflammatory agent or a functional derivative thereof; and a pharmaceutically acceptable excipient.
1 . A method for controlling or alleviating tissue destruction or dysfunction and pain by reducing the severity of inflammation and associated edema associated with a burn, comprising administering a pharmaceutical composition comprising a therapeutically effective amount of a pharmaceutically acceptable fluoride salt, in a pharmaceutically acceptable carrier, to a mammal in need thereof
2 . The method according to claim 1 , wherein the mammal is a human being.
3 . The method according to claim 1 , wherein the pharmaceutically acceptable fluoride salt comprises sodium fluoride.
4 . The method according to claim 1 , wherein the pharmaceutically acceptable fluoride salt comprises sodium fluoride in an amount of from 0.1 to 1.5% by weight per unit volume of the pharmaceutical composition.
5 . The method according to claim 1 , wherein the pharmaceutically effective amount is a dose of from 0.01 to 50 mg of the fluoride salt per 70 kg of body weight of said mammal.
6 . The method according to claim 1 , comprising administering the pharmaceutical composition topically to the burn.
7 . The method according to claim 6 , wherein the pharmaceutical composition is administered topically within 60 minutes after the mammal suffers the burn.
8 . The method according to claim 6 , wherein the pharmaceutical composition is administered topically within 10 to 20 minutes after the mammal suffers the burn.
9 . The method according to claim 6 , wherein the pharmaceutical composition is administered topically immediately after the mammal suffers the burn.
10 . The method according to claim 1 , comprising administering the pharmaceutical composition parenterally.
11 . The method according to claim 1 , wherein the pharmaceutical composition comprises a pharmaceutically acceptable solution, dispersion, suspension or emulsion.
12 . The method according to claim 1 , wherein administering the pharmaceutical composition comprises oral, systemic, implant, intravenous, topical, intrathecal, or nasal administration.
13 . The method according to claim 1 , wherein the pharmaceutically acceptable carrier comprises dicalcium phosphate, sodium metaphosphate, a thickening agent, a binder, monosodium phosphate, a pigment, a surfactant, and water.
14 . The method according to claim 1 , wherein the pharmaceutical composition comprises about 20 to 24% dicalcium phosphate dihydrate (DCP) by weight, about 11.5 to 15% insoluble sodium metaphosphate by weight, about 20 to 30% sorbitol syrup solution by weight, about 3.5 to 5% guar gum by weight, about 1.5 to 2% xanthan gum by weight, about 0.25 to 0.35% monosodium phosphate by weight, about 0.5 to 0.65% titanium dioxide by weight, about 0.4 to 0.5% sodium dodecylbenzene sulphate by weight, about 15 to 30% water by weight, about 0.65 to 0.85% trimagnesium phosphate by weight, and about 2.5 to 3.5% hydroxethyl cellulose ester by weight.
15 . The method according to claim 1 , wherein the pharmaceutical composition comprises about 0.01 to 0.1 M of the pharmaceutically acceptable fluoride salt.
16 . The method according to claim 1 , wherein the burn is a second degree burn, a third degree burn, a fourth degree burn, or any combination thereof
17 . The method according to claim 1 , wherein the pharmaceutically acceptable fluoride salt comprises one or more of NaF, KF, LiF, NH 4 F, MgF 2 , CaF 2 , BaF 2 , SnF 2 , and AlF 3 .